NCT02892227已完成不适用
MANAGEMENT OF ACUTE HEART FAILURE: THE CONTRIBUTION OF DAILY 'BEDSIDE' ULTRASOUND TO THERAPEUTIC ADJUSTMENTS, WITH MEASURED IMPACT ON 30-DAY RE-HOSPITALISATION RATES
Centre Hospitalier Universitaire de Nīmes4 个研究点 分布在 1 个国家目标入组 250 人开始时间: 2016年11月15日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 250
- 试验地点
- 4
- 主要终点
- rehospitalization
研究概览
简要总结
Our hypothesis: a daily bedside echocardiographic assessment, protocolized, simple and reproducible estimation of filling pressures with an evaluation of mitral inflow and the inferior vena cava, allow a more reliable estimate of the true blood volume of the patient and thus lead to a therapeutic adjustment more suitable.
This therapeutic adjustment closer to patient's needs would impact fewer readmissions at 30 days and mortality, less alteration of biological parameters myocardial, kidney and liver.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient or his representative must be given free and informed consent and signed consent.
- •The patient must be affiliated or beneficiary of a health insurance plan.
- •The patient is available for a follow-up 6 months.
- •The patient is of age or older (>)
- •Patients hospitalized for acute heart failure who received at least 40mg of furosemide IV.
- •Patient with impaired LVEF <50%.
- •Patient with Nt-proBNP values> 1200pg / ml.
排除标准
- •The subject takes part in another study.
- •The subject is exclusion period determined by a previous study.
- •The subject is under judicial protection.
- •The subject or his representative refuses to sign the consent.
- •It is not possible to give the subject or his representative informed information.
- •Non-inclusion criteria for those diseases or conditions associated (s) interfere (s):
- •The patient is pregnant or is breastfeeding.
- •The patient is already included in a surveillance program (PRADO, OSICAT).
- •Patient with a mechanical or biological mitral prosthesis.
- •History of mitral stenosis.
- •severe valvular surgery with maturity in months (<30 days).
- •chronic renal impairment on dialysis.
- •High grade AV block (AVB and BAV3 2/1).
- •Hypertrophic cardiomyopathy.
- •Cardiogenic shock.
- •Contraindications to furosemide.
研究组 & 干预措施
JET ECHO
Experimental
Transmitral flow estimation
干预措施: Transmitral flow estimation (Procedure)
NO JET ECHO
No Intervention
no bedside echocardiography
结局指标
主要结局
rehospitalization
时间窗: 30 days
次要结局
- worsening heart failure(during hospitalization)
- average length of stay(during hospitalization)
- mortality(6 months)
- alteration of biological parameters myocardial, kidney and liver(Hospital discharge +7 days, Hospital discharge +30 days)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
2 期
B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot TrialHeart Failure AcuteAcute Cardiac Pulmonary EdemaAcute Cardiac FailureHeart FailureNCT03136198Indiana University130
Unknown
不适用
Development and Validation of a Simple-to-use Nomogram for Predicting In-hospital Mortality in Acute Heart Failure Patients Undergoing Continuous Renal Replacement TherapyHeart Failure AcuteNCT04751838Qilu Hospital of Shandong University226
已完成
不适用
Improving Diagnostic Accuracy for Acute Heart FailureDyspneaCardiac DyspneaAcute Heart FailureNCT04886128Vanderbilt University Medical Center2,469
Unknown
不适用
Does Ultrasound Assessment for Extravascular Lung Water and IVC Measurement Affect Outcomes in Inpatient Heart Failure Management?Acute Decompensated Heart FailureNCT04436718Riverside University Health System Medical Center400
已完成
不适用
Observational cohort study of acute heart failure in Yokohama, Yokohama Acute Heart Failure (YAHF) registryAcute heart failureJPRN-UMIN000010161Yokohama City University Medical Center450